Aberrant crypts as a biomarker for colon cancer: Evaluation of potential chemopreventive agents in the rat

Cancer Epidemiology Biomarkers and Prevention

Volumn 5, Issue 5, 1996, Pages 355-360

  Wargovich, Michael J ^a,c   Chen, Chi Dai ^a   Jimenez, Arnaldo ^a   Steele, Vernon E ^b   Velasco, Marco ^a   Stephens, L Clifton ^a   Price, Roger ^a   Gray, Kenneth ^a   Kelloff, Gary J ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 INDOLEMETHANOL; ALLYL SULFIDE; ARGININE; BIOCHEMICAL MARKER; BUTYLATED HYDROXYANISOLE; CROMOGLYCATE DISODIUM; CURCUMIN; EFLORNITHINE; FLUOCINOLONE ACETONIDE; FOLIC ACID ANTAGONIST; GALLIC ACID PROPYL ESTER; GLYCYRRHETINIC ACID; IBUPROFEN; INDOMETACIN; KETOPROFEN; LEVAMISOLE; MESNA; MOLYBDATE SODIUM; NONSTEROID ANTIINFLAMMATORY AGENT; OLTIPRAZ; PIROXICAM; PRASTERONE; PURPURIN; RUTOSIDE; SALAZOSULFAPYRIDINE; SITOSTEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER PREVENTION; COLON CANCER; COLON CARCINOGENESIS; CONTROLLED STUDY; GENE TARGETING; GROWTH INHIBITION; INTESTINE CRYPT; NONHUMAN; PRIORITY JOURNAL; STEM CELL;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AZOXYMETHANE; CARCINOGENS; CELL DIFFERENTIATION; CELL DIVISION; CHEMOPREVENTION; COLON; COLONIC NEOPLASMS; COLORING AGENTS; EVALUATION STUDIES; FORECASTING; INTESTINAL MUCOSA; MALE; METHYLENE BLUE; MINERALS; PREDICTIVE VALUE OF TESTS; RATS; RATS, INBRED F344; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; VITAMINS;

EID: 0029921139     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Boone, C. W., Kelloff, G. J., and Malone, W. E. Identification of candidate cancer chemopreventive agents and their evaluation in animal models and human clinical trials. Cancer Res., 50: 2-9, 1990.
2. Rao, C. V., Nayini, J., and Reddy, B. S. Effect of oltipraz 5′-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione on azoxymethane-induced biochemical changes re-lated to early colon carcinogenesis in male F344 rats. Proc. Soc. Exp. Biol. Med., 197: 77-84, 1991.
3. Wargovich, M. J., Allnutt, D., Palmer, C., Anaya, P., and Stephens, L. C. Inhibition of the promotional phase of azoxymethane-induced colon carcinogenesis in the F344 rat by calcium lactate: effect of simulating two human nutrient density levels. Cancer Lett., 53: 17-25, 1990.
4. Scalmati, A., and Lipkin, M. Proliferation and differentiation biomarkers in colorectal mucosa and their application to chemoprevention studies. Environ. Health Perspect., 99: 169-173, 1993.
5. Kulkami, N., Zang, E., Kelloff, G., and Reddy, B. S. Effect of the chemopreventive agents piroxicam and D,L-α-difluoromethylornithine on intermediate biomarkers of colon carcinogenesis. Carcinogenesis (Lond.), 13: 995-1000, 1992.
6. McLellan, E. A., and Bird, R. P. Aberrant crypts: potential preneoplastic lesions in the murine colon. Cancer Res., 48: 6187-6192, 1988.
7. Vivona, A. A., Shpitz, B., Medline, A., Bruce, W. R., Hay, K., Ward, M. A., Stern, H. S., and Gallinger, S. K-ras mutations in aberrant crypt foci, adenomas and adenocarcinomas during azoxymethane-induced colon carcinogenesis. Carcinogenesis (Lond.), 14: 1777-1781, 1993.
8. Pretlow, T. P., O'Riordan, M. A., Kolman, M. F., and Jurcisek, J. A. Colonic aberrant crypts in azoxymethane-treated F344 rats have decreased hexosaminidase activity. Am. J. Pathol., 136: 13-16, 1990.
9. McLellan, E. A., Medline, A., Bird, R. P. Sequential analyses of the growth and morphological characteristics of aberrant crypt foci: putative preneoplastic lesions. Cancer Res., 51: 5270-5274, 1991.
10. Berger, S. H., Haddox, M., and Wargovich, M. J. Biology of aberrant colonic crypts. Proc. Am. Assoc. Cancer Res., 35: 100, 1994.
11. Shpitz, B., Hay, K., Medline, A., Bruce, W. R., Vivona, A., Gallinger, S., Bull, S., and Stern, H. Aberrant crypt foci: early markers of malignancy in rat colon carcinogenesis. Proc. Am. Assoc. Cancer Res., 34: 115, 1993.
12. Wattenberg, L. W. Inhibitors of chemical carcinogenesis. Adv. Cancer Res., 26: 197-226, 1978.
13. Bird, R. P. Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. Cancer Lett., 37: 147-151, 1987.
14. Archer, M. C., Bruce, W. R., Chan, C. C., Corpet, D. E., Medline, A., Roncucci, L., Stamp, D., and Zhang, X. M. Aberrant crypt foci and microadenoma as markers for colon cancer. Environ. Health Perspect., 98: 195-197, 1992.
15. Sohn, O. S., Ishizaki, H., Yang, C. S., and Fiala, E. S. Metabolism of azoxymethane, methylazoxymethanol and W-nitrosodimethylamine by cytochrome P450IIE1. Carcinogenesis (Lond.), 12: 127-131, 1991.
16. Pretlow, T. P., O'Riordan, M. A., Pretlow, T. G., and Stellato, T. A. Aberrant crypts in human colonic mucosa: putative preneoplastic lesions. J. Cell. Biochem. Suppl., 16G: 55-62, 1992.
17. Roncucci, L. Early events in human colorectal carcinogenesis: aberrant crypts and microadenoma. Ital. J. Gastroenterol., 24: 498-501, 1992.
18. Bruce, W. R. Aberrant crypt foci in the detection of colon carcinogens. Prog. Clin. Biol. Res., 347: 129-137, 1990.
19. Lam, L. K. T., and Zhang, J. Reduction of aberrant crypt formation in the colon of CF1 mice by potential chemopreventive agents. Carcinogenesis (Lond.), 12: 2311-2315, 1991.
20. Pereira, M. A., and Khoury, M. D. Prevention by chemopreventive agents of azoxymethane-induced foci of aberrant crypts in rat colon. Cancer Lett., 61: 27-33, 1991.